May 9 |
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
|
May 7 |
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
|
May 3 |
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
|
May 2 |
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
|
May 2 |
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuardĀ® Esophageal Precancer Testing
|
May 1 |
Veris teams up with Ohio University for cancer digital health pilot
|
Apr 30 |
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
|
Apr 29 |
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
|
Apr 10 |
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
|
Apr 8 |
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
|